Myfortic

DRUG20 trials

Sponsors

Novartis Pharmaceuticals, The University of Texas Health Science Center, Houston, European Society for Blood and Marrow Transplantation, University of Florida, University of Pittsburgh

Conditions

Antibody Mediated RejectionCarcinoma, HepatocellularChronic Renal InsufficiencyEnd Stage Renal DiseaseGastrointestinal LesionsGraft vs Host DiseaseHeart Transplant PatientsImmunosuppression

Phase 1

Desensitization of Renal Transplant Candidates

CompletedNCT00298883

University of FloridaEnd Stage Renal Disease, Kidney Transplantation

Start: 2006-02-28End: 2008-12-31Updated: 2012-07-25

Phase 2

Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation

Armin GoralczykChronic Renal Insufficiency, Liver Transplantation

Start: 2010-01-31End: 2013-01-31Target: 29Updated: 2011-09-15

Phase 3

Freedom Study: Myfortic in Kidney Transplant Patients

CompletedNCT00101738

Novartis PharmaceuticalsKidney Transplantation

Start: 2003-03-31End: 2005-05-31Updated: 2011-01-31

Myfortic - Treatment for Extensive cGvHD

TerminatedNCT00298324

European Society for Blood and Marrow TransplantationGraft vs Host Disease

Start: 2006-09-30End: 2010-11-30Updated: 2015-04-03

Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms

McGill University Health Centre/Research Institute of the McGill University Health CentreHeart Transplant Patients

Start: 2007-05-31End: 2009-12-31Target: 100Updated: 2008-10-17

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

CompletedNCT00514514

Novartis PharmaceuticalsKidney Transplantation

Start: 2007-07-31End: 2015-06-30Updated: 2017-01-18

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

CompletedNCT01079143

Novartis PharmaceuticalsRenal Interstitial Fibrosis

Start: 2009-09-30End: 2012-06-30Updated: 2014-03-18

Myfortic for the Treatment of Non-infectious Intermediate Uveitis

CompletedNCT01092533

STZ eyetrialUveitis, Intermediate

Start: 2010-03-31End: 2015-10-31Updated: 2017-05-09

Phase 4

Enteric Coated Myfortic for Liver Transplant Recipients

WithdrawnNCT00167492

The University of Texas Health Science Center, HoustonLiver Transplantation

Start: 2005-09-30End: 2009-02-28Updated: 2013-12-09

Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

CompletedNCT00585468

University of UtahKidney Transplantation

Start: 2007-12-31End: 2011-07-31Updated: 2016-05-06

Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®

CompletedNCT00652834

University of California, Los AngelesGastrointestinal Lesions, Signs and Symptoms, Digestive

Start: 2009-04-30End: 2011-05-31Updated: 2016-03-04

Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)

Foothills Medical CentreKidney Transplant

Start: 2006-07-31End: 2008-09-30Target: 110Updated: 2008-05-15

A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients

CompletedNCT01018914

Astellas Pharma IncLiver Transplantation

Start: 2009-04-30End: 2010-12-31Updated: 2016-01-29

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

Enrolling by invitationNCT02081755

Baylor Research InstituteCarcinoma, Hepatocellular

Start: 2014-03-01End: 2027-03-01Target: 336Updated: 2026-01-27

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

WithdrawnNCT02130817

University of Wisconsin, MadisonAntibody Mediated Rejection, End Stage Renal Disease

Start: 2014-09-24End: 2015-10-09Updated: 2018-12-17

Unknown Phase

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

CompletedNCT00336817

University of PittsburghImmunosuppression

Start: 2006-11-30End: 2008-11-30Updated: 2017-03-09

Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

CompletedNCT00336895

University of PittsburghImmunosuppression

Start: 2006-11-30End: 2008-11-30Updated: 2016-11-07

Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study

Genovate Biotechnology Co., Ltd.,Uveitis

Start: 2009-01-31End: 2011-12-31Target: 40Updated: 2010-12-16

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

RecruitingNCT01999361

Rodolfo AlejandroType 1 Diabetes Mellitus

Start: 2009-01-01End: 2028-12-01Target: 18Updated: 2026-03-23

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

CompletedNCT04645589

Novartis PharmaceuticalsLupus Nephritis

Start: 2021-03-16End: 2025-06-13Updated: 2025-12-09

Related Papers

Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study

BMJ Open2021-10-0140 citations

Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study

BMJ2019-09-17310 citations

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials.

2018-09-1912 citations

Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.

2017-06-0131 citations

Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients.

2012-05-0117 citations

A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.

2010-04-098 citations